Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway

Cancer Biology and Therapy

Volumn 10, Issue 3, 2010, Pages 251-257

  Ren, Tingting ^a   Guo, Wei ^a   Peng, Changliang ^a   Lu, Xinchang ^a   Yang Yi, ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

Arsenic trioxide; HOS; Invasion; MAPK; Migration; MNNG; Osteosarcoma

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ARSENIC TRIOXIDE; BETA ACTIN; F ACTIN; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL ADHESION; CELL MOTILITY; CHINESE MEDICINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOSKELETON; ENZYME ACTIVITY; ENZYME INACTIVATION; HUMAN; HUMAN CELL; METASTASIS INHIBITION; OSTEOSARCOMA CELL; PROTEIN FAMILY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 77955496138     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.3.12349     Document Type: Article

References (25)

1. Heare T, Hensley MA, Dell'Orfano S. Bone tumors: osteosarcoma and Ewing's sarcoma. Current Opinion in Pediatrics 2009; 21:365-72.
2. Souhami RL, Craft AW, Van der Eijken JW, Nooij M, Spooner D, Bramwell VH, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. Lancet 1997; 350:911-7.
3. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106:1154-61. (Pubitemid 43297356)
4. Bielack SS, Kempf BB, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-90.
5. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol 2002; 20:426-33.
6. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP. Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proceedings of the National Academy of Sciences of the United States of America 2000; 97:10173-8.
7. Wang ZY. Arsenic compounds as anticancer agents. Cancer Chemotherapy & Pharmacology 2001; 48:72-6.
8. Bachleitner HT, Kees M, Gisslinger H. Arsenic trioxide: acute promyelocytic leukemia and beyond. Leukemia & lymphoma 2002; 43:1535-40. (Pubitemid 34823475)
9. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer research 2002; 62:3893-903.
10. Berenson JR, Yeh HS. Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy. Clinical lymphoma & myeloma 2006; 7:192-8.
11. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH. Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 2007; 25:77-84.
12. Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z. Arsenic trioxide, a therapeutic agent for APL. Oncogene 2001; 20:7146-53.
13. Halicka HD, Smolewski P, Darzynkiewicz Z, Dai W, Traganos F. Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell cycle 2002; 1:201-9.
14. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer research 1999; 59:6033-7.
15. Danaee H, Nelson HH, Liber H, Little JB, Kelsey KT. Low dose exposure to sodium arsenite synergistically interacts with UV radiation to induce mutations and alter DNA repair in human cells. Mutagenesis 2004; 19:143-8. (Pubitemid 38380290)
16. Zhao H, Guo W, Peng C, Ji T, Lu X. Arsenic trioxide inhibits the growth of Adriamycin resistant osteosarcoma cells through inducing apoptosis. Mol Biol Rep 2009; doi: 10.1007/s11033-009-9765-2.
17. Guo W, Tang XD, Tang S, Yang Y. Preliminary report of combination chemotherapy including Arsenic trioxide for stage III osteosarcoma and Ewing sarcoma. Zhonghua wai ke za zhi 2006; 44:805-8.
18. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer research 2001; 61:5432-40.
19. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, et al. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 2000; 6:4957-64.
20. Xiao T, Li KH, Fang JZ. Experimental study on the apoptotic effect of arsenic trioxide on human osteosarcoma MG-63 cells. Hunan yi ke da xue xue bao 2002; 27:111-3.
21. Shen ZY, Shen J, Cai WJ, Hong C, Zheng MH. The alteration of mitochondria is an early event of arsenic trioxide induced apoptosis in esophageal carcinoma cells. International Journal of Molecular Medicine 2000; 5:155-8.
22. Lin TH, Kuo HC, Chou FP, Lu FJ. Berberine enhances inhibition of glioma tumor cell migration and invasiveness mediated by arsenic trioxide. BMC cancer 2008; DOI: 10.1186/1471-2407-8-58.
23. 3) reduces the invasive and metastatic properties of cervical cancer cells in vitro and in vivo. Gynecologic oncology 2007; 106:400-6.
24. Park MJ, Lee JY, Kwak HJ, Park CM, Lee HC, Woo SH, et al. Arsenic trioxide inhibits invasion of HT1080 human fibrosarcoma cells: role of nuclear factor-kappaB and reactive oxygen species. J Cell Biochem 2005; 95:955-69.
25. Mathieu J, Besançon F. Clinically tolerable concentrations of arsenic trioxide induce p53-independent cell death and repress NFkappaB activation in Ewing sarcoma cells. Int J Cancer 2006; 119:1723-7. (Pubitemid 44258783)